TCGA-FD-A5C1-01A-11R-A28M-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 58.86990802
- os_event
- false
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.690
- INTERFERON_GAMMA_RESPONSE+0.640
- ALLOGRAFT_REJECTION+0.560
- TNFA_SIGNALING_VIA_NFKB+0.550
- IL6_JAK_STAT3_SIGNALING+0.520
- INFLAMMATORY_RESPONSE+0.510
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.480
- COAGULATION+0.440
- COMPLEMENT+0.430
- APOPTOSIS+0.380
Top 10 suppressed
- MITOTIC_SPINDLE-0.230
- WNT_BETA_CATENIN_SIGNALING-0.150
- UV_RESPONSE_DN-0.110
- FATTY_ACID_METABOLISM-0.070
- PEROXISOME-0.030
- SPERMATOGENESIS-0.020
- HEME_METABOLISM-0.010
- PROTEIN_SECRETION+0.010
- KRAS_SIGNALING_DN+0.030
- G2M_CHECKPOINT+0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AE47BCDE-A2D2-43EF-8EC7-78E4D1817EEE | — | — | 0.927 |
| 2 | MDT-AP-2001 | Med | Medulloblastoma | 0.924 |
| 3 | TCGA-ZF-AA53-01A-11R-A39I-07 | — | — | 0.922 |
| 4 | TCGA-FD-A6TD-01A-51R-A33J-07 | — | — | 0.920 |
| 5 | TCGA-UY-A78P-01A-12R-A36F-07 | — | — | 0.914 |
| 6 | 5063882F-6377-4976-BB48-7275D46C44E6 | — | — | 0.911 |
| 7 | TCGA-ZF-A9RD-01A-11R-A42T-07 | — | — | 0.907 |
| 8 | TCGA-22-0940-01A-01R-0692-07 | — | cohortSQ1 | 0.907 |
| 9 | TCGA-66-2765-01A-01R-0851-07 | — | cohortSQ1 | 0.904 |
| 10 | BS_M8WP5T16 | low-grade glioma | — | 0.902 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.690 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.640 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.560 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.550 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.520 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.510 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.480 | Inavolisib | — uncovered |
| COAGULATION | 0.440 | Binimetinib | — uncovered |
| COMPLEMENT | 0.430 | Inavolisib | — uncovered |
| APOPTOSIS | 0.380 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.370 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.340 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.310 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |